|
Synonyms: Anxu® (China) | example 5 [US10561657B2] | TQ-05105 | TQ05105
rovadicitinib is an approved drug
Compound class:
Synthetic organic
Comment: This is the chemical structure for the INN rovadicitinib. The structure is claimed in patent US10561657B2, as a Janus kinase (JAK) inhibitor [4]. It later transpired that rovadicitinib (TQ05105) was a dual JAK1/2 and Rho kinase (ROCK) 1/2 inhibitor [5].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| Rovadicitinib was progressed as a clinical candidate for the treatment of the inflammatory and fibrotic components of myelofibrotic conditions [3], and chronic graft-versus-host disease (cGVHD) [5]. It was first approved in China in early 2026, to treat primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis [1]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT04339400 | A Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms | Phase 1 Interventional | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | ||
| NCT05020652 | A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis | Phase 2 Interventional | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | ||
| NCT06300320 | A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease | Phase 2 Interventional | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | ||
| NCT04944043 | A Study of TQ05105 in Patients With Chronic Graft Versus Host Disease | Phase 1/Phase 2 Interventional | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 5 | |
| NCT06388759 | TQ05105 Tablet for Myelofibrosis Treatment in Ruxolitinib-Resistant or Intolerant Patients | Phase 1 Interventional | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2 | |